Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Other Non-Current Liabilities (2024 - 2025)

Crinetics Pharmaceuticals (CRNX) has 2 years of Other Non-Current Liabilities data on record, last reported at $3.2 million in Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 290.83% year-over-year to $3.2 million; the TTM value through Dec 2025 reached $3.2 million, up 290.83%, while the annual FY2025 figure was $3.2 million, 290.83% up from the prior year.
  • Other Non-Current Liabilities reached $3.2 million in Q4 2025 per CRNX's latest filing, up from $2.9 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $3.2 million in Q4 2025 and bottomed at $202000.0 in Q2 2024.